Get started
Author

Munenobu Kashiwa

Observed name: Munenobu Kashiwa,
ORCID: 0000-0001-5178-611X
Observed ORCID: 0000-0001-5178-611X
OpenAlex ID: A5075462361
Comparative Cost-utility Analysis of Regorafenib and Trifluridine/Tipiracil in The Treatment of Metastatic Colorectal Cancer in Japan
2020 · Munenobu Kashiwa, Ryo Matsushita · Clinical Therapeutics · 14
Comparative Cost-effectiveness of Aflibercept and Ramucirumab in Combination with Irinotecan and Fluorouracil-based Therapy for the Second-line Treatment of Metastatic Colorectal Cancer in Japan
2020 · Munenobu Kashiwa,, Ryo Matsushita · Clinical Therapeutics · 12
Cost-utility analysis of palonosetron in the antiemetic regimen for cisplatin-containing highly emetogenic chemotherapy in Japan
2019 · Munenobu Kashiwa, Ryo Matsushita · BMC Health Services Research · 9
PDF
Comparative Cost-utility Analysis Between Aprepitant- and Fosaprepitant-containing Regimens To Prevent Chemotherapy-induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy in Japan
2019 · Munenobu Kashiwa, Ryo Matsushita · Clinical Therapeutics · 9
Comparative Cost-Effectiveness of Atezolizumab Versus Durvalumab as First-Line Combination Treatment with Chemotherapy for Patients with Extensive-Disease Small-Cell Lung Cancer in Japan
2024 · Munenobu Kashiwa, Miho Tsukada, et al. · Clinical Drug Investigation · 4
PDF
Comparative Cost-Effectiveness of Gemcitabine and Cisplatin in Combination with S-1, Durvalumab, or Pembrolizumab as First-Line Triple Treatment for Advanced Biliary Tract Cancer
2024 · Munenobu Kashiwa, Hiroyuki Maeda · Journal of Gastrointestinal Cancer · 4
Model-based cost-utility analysis of gemcitabine, cisplatin, and S-1 as triple therapy for advanced biliary tract cancer
2023 · Munenobu Kashiwa, Ryo Matsushita · International Journal of Clinical Pharmacy · 4
PDF
Difference in Cost-Effectiveness between First-Line and Third-Line or Later Nivolumab Therapy in Patients with HER2-Negative, Unresectable, Advanced or Recurrent Gastric or Gastro-Esophageal Junction Cancer in Japan
2022 · Munenobu Kashiwa, Ryo Matsushita · Biological and Pharmaceutical Bulletin · 4
PDF
Cost-effectiveness of preemptive skin treatment to prevent skin-toxicity caused by panitumumab in third-line therapy for KRAS wild type metastatic colorectal cancer in Japan
2021 · Munenobu Kashiwa, Ryo Matsushita · Journal of Pharmaceutical Health Care and Sciences · 3
PDF
Comparative cost-effectiveness of nivolumab first-line and second-line therapy for advanced esophageal cancer in Japan
2023 · Munenobu Kashiwa · The European Journal of Health Economics · 2
EE374 Cost-Effectiveness Analysis of Dostarlimab Plus Chemotherapy As First-Line Treatment for Metastatic Non-Squamous Non-Small Cell Lung Cancer in Japan
2025 · Kureha Kawai, Kensuke Moriwaki, et al. · Value in Health · 1
Ee98 Comparative Cost-effectiveness of First Line Therapy for Metastatic or Recurrent Pancreatic Cancer in Japan
2026 · INOUE MAHO, Kosuke MORIMOTO, et al. · Value in Health Regional Issues
Healthcare Cost Patterns in CDK4/6 Inhibitor-Treated HR+/HER2- Metastatic Breast Cancer
2026 · Munenobu Kashiwa, Kensuke Moriwaki · Clinical Drug Investigation
PDF
Cost-Effectiveness Analysis of Anamorelin and Olanzapine for Cancer Cachexia in Non-Small Cell Lung Cancer Patients in Japan
2026 · Munenobu Kashiwa, Tatsuya Nishikawa · Value in Health Regional Issues
Difference in Cost-Effectiveness of Trastuzumab Deruxtecan in First-Line Versus Later-Line Settings for HER2-Low Metastatic Breast Cancer
2026 · Munenobu Kashiwa, Maya Fujimori · Annals of Pharmacotherapy
Economic Burden of Cachexia in Japanese Lung Cancer Patients: A Retrospective Claims Database Analysis
2026 · Munenobu Kashiwa · Biological and Pharmaceutical Bulletin
Rwd271 Sequential Cdk4/6 Inhibitor Therapy Versus Mtor Inhibitor Therapy Following Initial Cdk4/6 Inhibitor in Hr+/her2- Advanced Breast Cancer
2025 · Munenobu Kashiwa, Kosuke MORIMOTO, et al. · Value in Health Regional Issues
PDF
EE90 Cost-Effectiveness Analysis of NALIRIFOX as First-Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma in Japan
2025 · Sara Izumi, Kensuke Moriwaki, et al. · Value in Health
EE76 A Model-Based Cost-Effectiveness Analysis of Anamorelin and Olanzapine in NSCLC Cachexia Treatment in Japan
2025 · Munenobu Kashiwa, Tatsuya Nishikawa, et al. · Value in Health
EE268 Cost-Effectiveness Analysis of Mirvetuximab Soravtansine in FRa-Positive Platinum-Resistant Ovarian Cancer in Japan
2025 · Kano Miki, Kensuke Moriwaki, et al. · Value in Health
EE160 Cost-Effectiveness Analysis of Tripalimumab for Metastatic or Recurrent Triple-Negative Breast Cancer in Japan
2025 · Momoha Kabuto, Kensuke Moriwaki, et al. · Value in Health
Works count: 21
Citation count: 66
H-index: 4
I10-index: 2
Year
Topic
Type